Agios Pharmaceuticals (NASDAQ: AGIO) recently received a number of ratings updates from brokerages and research firms:
- 7/31/2026 – Agios Pharmaceuticals had its price target raised by Citigroup Inc. from $46.00 to $52.00. They now have a “buy” rating on the stock.
- 7/31/2026 – Agios Pharmaceuticals had its price target lowered by Truist Financial Corporation from $41.00 to $39.00. They now have a “buy” rating on the stock.
- 7/30/2026 – Agios Pharmaceuticals had its price target raised by HC Wainwright from $52.00 to $55.00. They now have a “buy” rating on the stock.
- 7/21/2026 – Agios Pharmaceuticals had its price target lowered by HC Wainwright from $54.00 to $52.00. They now have a “buy” rating on the stock.
- 7/7/2026 – Agios Pharmaceuticals had its price target raised by Royal Bank Of Canada from $28.00 to $32.00. They now have a “sector perform” rating on the stock.
- 7/7/2026 – Agios Pharmaceuticals had its price target raised by Truist Financial Corporation from $36.00 to $41.00. They now have a “buy” rating on the stock.
- 7/7/2026 – Agios Pharmaceuticals had its price target raised by Bank of America Corporation from $40.00 to $46.00. They now have a “buy” rating on the stock.
- 6/24/2026 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by Weiss Ratings.
- 6/11/2026 – Agios Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $36.00 to $31.00. They now have a “neutral” rating on the stock.
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
Featured Stories
- Five stocks we like better than Agios Pharmaceuticals
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
